Lodenosine

Drug Profile

Lodenosine

Alternative Names: 2'-F-dd-ara-A; 2'-Fluoro-2',3'-dideoxyarabinosyladenine; DDG 1; FddA; Fddl; NSC 613792

Latest Information Update: 11 Jan 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer MedImmune Oncology; National Institutes of Health (USA)
  • Class Antiretrovirals; Dideoxynucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 11 Jan 2001 Discontinued-II for HIV infections treatment in Brazil (PO)
  • 11 Jan 2001 Discontinued-II for HIV infections treatment in United Kingdom (PO)
  • 11 Jan 2001 Discontinued-II for HIV infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top